Senior Scientist or Principal Scientist, Targeted Proteomics

Who We Are

: Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on building an industry-leading pipeline of oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions.

Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years. com or follow us on X (formerly Twitter) or LinkedIn . How we work: PIONEER : We are courageous, resilient and rigorous in our mission to improve patients’ lives through our revolutionary degrader medicines.

COLLABORATE : We value trust + transparency from everyone. Our goals are shared, our decisions data-driven and our camaraderie genuine. BELONG : We recognize our differences, inviting curiosity and inclusivity, so that our people are valued, seen, and heard.

How you’ll make an impact: Scientific Leadership and Experimental Strategy : Partner with cross-functional project teams to define key scientific questions that can be addressed by targeted proteomics. Collaborate with stakeholders to prioritize studies based on urgency and program impact. Translate key program questions into targeted proteomics experiments, execute studies analyze and interpret data, and communicate the findings to cross-function teams to enable program decision-making.

Targeted Proteomics and Assay Development : Drive TPD research programs through development and application of targeted protein mass spectrometry (MS) assays using state-of-the-art LC-MS systems—including nano-LC and Orbitrap platforms. g. cells, tissues, biofluids) from both human and preclinical species.

Develop, optimize, qualify and transfer targeted proteomics assays to support preclinical and clinical studies. Innovate and implement new targeted proteomics analysis workflows, including automated enrichment strategies, to enable sensitive, precise, and scalable protein quantification. External Collaboration and Communication : Lead and oversee proteomics activities at CRO partners, including assay transfer, qualification, execution, and data quality oversight.

Present scientific findings and strategic recommendations to project teams, senior leadership, and external collaborators in a clear, concise, and impactful manner. Skills and experience you’ll bring: PhD in Biochemistry, Biology, Chemistry, or Chemical Biology with a minimum of 2 years of experience in targeted, mass spectrometry–based proteomics in an industry or startup biotech setting; or BS/MS with 8+ years of relevant experience. Domain expertise in targeted proteomics, including: Demonstrated ability in translating key biological and pharmacodynamic questions into targeted proteomics strategies that inform discovery, translational, and clinical-stage decision making within fast-paced drug discovery environments.

Development and deployment of highly multiplexed and sensitive PRM or MRM stable isotope–labeled peptide assays using DDA and DIA data. Development of immunoaffinity enrichment methods to enhance MS assay sensitivity. Knowledge of techniques for optimizing protein recovery from complex biological matrices (cells, tissues, biofluids) derived from human and preclinical species.

Operation, maintenance, and troubleshooting of nanoLC and Orbitrap MS instrumentation. Quantitative analysis and report generation using Skyline and related quantitative proteomics data analysis tools.